Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients With Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer

• Published in: Journal of clinical oncology Vol. 17; no. 3; p. 902
• Main Authors: Scheithauer, W, Kornek, G V, Raderer, M, Valencak, J, Weinländer, G, Hejna, M, Haider, K, Kwasny, W, Depisch, D
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 01.03.1999
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Chemotherapy, Adjuvant; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor - administration & dosage; Hematologic Diseases - chemically induced; Humans; Male; Middle Aged; Nausea - chemically induced; Organoplatinum Compounds - administration & dosage

To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer pretreated with leucovorin-modulated fluoropyrimidines. Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinui...